-
Onyx Therapeutics, Inc. v. CIPLA Limited et al DC CAFC
- 1:16-cv-00988
- D. Del.
- Judge: Gregory B. Williams
- Filed: 10/24/2016
- Closed: 02/21/2023
- Latest Docket Entry: 02/21/2023
- PACER
1
Plaintiff
16
Defendants
2
Accused
Products
9
Patents-in-Suit
2,312
Days in
Litigation
-
Onyx Therapeutics, Inc. v. CIPLA Limited et al DC CAFC
- 1:16-cv-00988
- D. Del.
- Judge: Gregory B. Williams
- Filed: 10/24/2016
- Closed: 02/21/2023
- Latest Docket Entry: 02/21/2023
- PACER
Cause of Action
Willful Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 31 |
A pharmaceutical composition comprising a compound having a structure</claim-text> <chemistry id="CHEM-US-00046" num="00046"><img id="EMI-C00046" he="35.64mm" wi="74.59mm" file="US07737112-20100615-C00046.TIF" alt="embedded image" img-content="chem"
view more
|
Enforceable and Valid
Entry 549 |
| 32 |
A pharmaceutical composition in the form of a lyophilisate comprising SBECD and a compound having a structure</claim-text> <chemistry id="CHEM-US-00047" num="00047"><img id="EMI-C00047" he="35.64mm" wi="74.59mm" file="US07737112-20100615-C00047.TIF"
view more
|
Enforceable and Invalid
Entry 549 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 23 |
A compound of claim 22 or a pharmaceutically acceptable salt thereof, wherein R<sup>6 </sup>and R<sup>8 </sup>are both isobutyl.
|
Enforceable and Valid
Entry 549 |
| 24 |
A compound of claim 19 or a pharmaceutically acceptable salt thereof, having the following structure</claim-text>
|
Enforceable and Valid
Entry 549 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A compound having the formula: <chemistry id="CHEM-US-00031" num="00031"><img id="EMI-C00031" he="34.63mm" wi="72.31mm" file="US08207125-20120626-C00031.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry>
|
Enforceable and Valid
Entry 549 |
-
Infringement
Cipla (EU) Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic carfilzomib 60 mg lyophilized powder for reconstitution | US 7,417,042 B2 |
23, 24
|
Infringement
Entry 549
|
| Generic carfilzomib 60 mg lyophilized powder for reconstitution | US 7,737,112 B2 |
31, 32
|
Infringement
Entry 549
|
| Generic carfilzomib 60 mg lyophilized powder for reconstitution | US 8,207,125 B2 |
1
|
Infringement
Entry 549
|
Cipla USA Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic carfilzomib 60 mg lyophilized powder for reconstitution | US 7,417,042 B2 |
23, 24
|
Infringement
Entry 549
|
| Generic carfilzomib 60 mg lyophilized powder for reconstitution | US 7,737,112 B2 |
31, 32
|
Infringement
Entry 549
|
| Generic carfilzomib 60 mg lyophilized powder for reconstitution | US 8,207,125 B2 |
1
|
Infringement
Entry 549
|
